MCID: BNG030
MIFTS: 48

Benign Ependymoma

Categories: Cancer diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Benign Ependymoma

MalaCards integrated aliases for Benign Ependymoma:

Name: Benign Ependymoma 12 15
Ependymoma 44 72
Who Grade Ii Ependymal Tumor 12
Myxopapillary Ependymoma 72
Epithelial Ependymoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4844
MeSH 44 D004806
NCIt 50 C3017
SNOMED-CT 68 57706008
UMLS 72 C0014474 C0205769

Summaries for Benign Ependymoma

MalaCards based summary : Benign Ependymoma, also known as ependymoma, is related to cellular ependymoma and anaplastic ependymoma, and has symptoms including back pain An important gene associated with Benign Ependymoma is TSC2 (TSC Complex Subunit 2), and among its related pathways/superpathways are Regulation of lipid metabolism Insulin signaling-generic cascades and Type I Interferon Signaling Pathways. The drugs Temozolomide and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells, and related phenotypes are behavior/neurological and nervous system

Related Diseases for Benign Ependymoma

Diseases in the Ependymoma family:

Benign Ependymoma Malignant Ependymoma
Malignant Adult Ependymoma

Diseases related to Benign Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 510)
# Related Disease Score Top Affiliating Genes
1 cellular ependymoma 34.3 SYP GFAP
2 anaplastic ependymoma 34.3 SYP NF2 GFAP
3 malignant ependymoma 34.1 NF2 GFAP
4 clear cell ependymoma 33.8 SYP GFAP ENO2
5 spinal cord ependymoma 33.5 NF2 EPB41L3
6 papillary ependymoma 33.2 SYP RBFOX3 GFAP ENO2
7 glioma susceptibility 1 33.2 IDH1 GFAP
8 tanycytic ependymoma 33.0 SYP RBFOX3 NF2 GFAP
9 subependymoma 32.2 TSC2 SYP GFAP ENO2
10 medulloblastoma 31.9 SYP IDH1 GFAP ENO2
11 obstructive hydrocephalus 31.2 SYP GFAP
12 papilloma of choroid plexus 31.1 SYP GFAP
13 spinal meningioma 31.1 NF2 ENO2
14 hydrocephalus 31.1 SYP GFAP ENO2
15 pilocytic astrocytoma 31.0 IDH1 GFAP
16 teratoma 30.8 SYP GFAP ENO2
17 neurilemmoma 30.8 NF2 GFAP ENO2
18 medulloepithelioma 30.7 SYP GFAP
19 hemangioblastoma 30.7 SYP GFAP ENO2
20 rhabdoid meningioma 30.7 NF2 GFAP
21 mixed glioma 30.6 IDH1 GFAP
22 central neurocytoma 30.6 SYP GFAP ENO2
23 fibrillary astrocytoma 30.5 IDH1 GFAP
24 tuberous sclerosis 1 30.5 TSC2 TSC1 MTOR
25 gangliocytoma 30.5 SYP RBFOX3
26 congenital heart defects, hamartomas of tongue, and polysyndactyly 30.5 TSC2 TSC1
27 chordoid meningioma 30.4 SYP GFAP
28 meningioma, radiation-induced 30.4 NF2 GFAP EPB41L3
29 glioblastoma multiforme 30.3 MTOR IDH1 GFAP
30 papillary tumor of the pineal region 30.3 SYP ENO2
31 malignant teratoma 30.3 SYP ENO2
32 oligodendroglioma 30.3 SYP IDH1 GFAP ENO2
33 ganglioneuroblastoma 30.3 SYP ENO2
34 angiocentric glioma 30.3 SYP IDH1 GFAP
35 cystic teratoma 30.2 SYP GFAP ENO2
36 rhabdoid cancer 30.2 SYP ENO2
37 pineoblastoma 30.2 SYP GFAP
38 tuberculum sellae meningioma 30.2 SYP RBFOX3
39 gliosarcoma 30.2 IDH1 GFAP ENO2
40 spinal cancer 30.2 NF2 GFAP
41 astroblastoma 30.1 SYP GFAP ENO2
42 ganglioneuroma 30.1 SYP GFAP ENO2
43 granular cell tumor 30.1 GFAP ENO2
44 spinal cord astrocytoma 30.0 IDH1 GFAP
45 pilomyxoid astrocytoma 30.0 SYP GFAP
46 cauda equina neoplasm 30.0 SYP RBFOX3 ENO2
47 pleomorphic xanthoastrocytoma 30.0 SYP IDH1 GFAP
48 neuroma 29.9 NF2 GFAP ENO2
49 pineal gland cancer 29.9 SYP GFAP ENO2
50 pineocytoma 29.9 SYP GFAP ENO2

Graphical network of the top 20 diseases related to Benign Ependymoma:



Diseases related to Benign Ependymoma

Symptoms & Phenotypes for Benign Ependymoma

UMLS symptoms related to Benign Ependymoma:


back pain

MGI Mouse Phenotypes related to Benign Ependymoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.56 ENO2 EPB41L3 GFAP MTOR NF2 SYP
2 nervous system MP:0003631 9.23 ENO2 EPB41L3 GFAP MTOR NF2 SYP

Drugs & Therapeutics for Benign Ependymoma

Drugs for Benign Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 310)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 2, Phase 3 85622-93-1 5394
2
Donepezil Approved Phase 3 120014-06-4 3152
3
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
6
Ondansetron Approved Phase 3 99614-02-5 4595
7
Valproic acid Approved, Investigational Phase 2, Phase 3 99-66-1 3121
8
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
9
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
10
Histamine Approved, Investigational Phase 3 51-45-6 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
13 Trofosfamide Investigational Phase 2, Phase 3 22089-22-1
14
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
15 Cholinesterase Inhibitors Phase 3
16 Cholinergic Agents Phase 3
17 Nootropic Agents Phase 3
18 Cola Phase 3
19 Analgesics Phase 3
20 Anesthetics, Intravenous Phase 3
21 Narcotics Phase 3
22 Analgesics, Opioid Phase 3
23 Adjuvants, Anesthesia Phase 3
24 Anesthetics, General Phase 3
25 Emetics Phase 3
26 Anticonvulsants Phase 2, Phase 3
27 Central Nervous System Depressants Phase 2, Phase 3
28 Keratolytic Agents Phase 3
29 Podophyllotoxin Phase 3 518-28-5
30 Psychotropic Drugs Phase 2, Phase 3
31 Tranquilizing Agents Phase 2, Phase 3
32 GABA Agents Phase 2, Phase 3
33 Antimanic Agents Phase 2, Phase 3
34 Central Nervous System Stimulants Phase 3
35 Neurotransmitter Agents Phase 3
36 Dexmethylphenidate Hydrochloride Phase 3
37 Neurotransmitter Uptake Inhibitors Phase 3
38 Dopamine Uptake Inhibitors Phase 3
39 Dopamine Agents Phase 3
40
Histamine Phosphate Phase 3 51-74-1 65513
41 Serotonin Antagonists Phase 3
42 Anti-Allergic Agents Phase 3
43 Histamine H1 Antagonists Phase 3
44 Histamine Antagonists Phase 3
45 Serotonin Agents Phase 3
46 Antipruritics Phase 3
47
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
48
Aminolevulinic acid Approved Phase 2 106-60-5 137
49
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
50
Lenograstim Approved, Investigational Phase 2 135968-09-1

Interventional clinical trials:

(show top 50) (show all 259)
# Name Status NCT ID Phase Drugs
1 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
3 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
4 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
6 Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents Completed NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;intraventricular etoposide;trofosfamide, etoposide
7 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years Recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine Sulfate Liposome
8 An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
9 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
10 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
11 Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
12 Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
13 A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
14 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
15 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
16 Proton Radiation for Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
17 Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
18 A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS Completed NCT00002876 Phase 2 cisplatin;etoposide
19 A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
20 PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS Completed NCT00002752 Phase 1, Phase 2
21 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
22 Improved Characterization of Brain Tumors By MRI and MRS Completed NCT00274755 Phase 2 chemotherapy
23 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
24 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
25 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
26 A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
27 SIOP Study of Combined Modality Treatment in Childhood Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
28 A Phase II Study of Pemetrexed in Children With Recurrent Malignancies Completed NCT00520936 Phase 2 pemetrexed
29 A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
30 A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects Completed NCT00187226 Phase 2
31 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
32 A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients Completed NCT01462695 Phase 2 Sunitinib Malate
33 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
34 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
35 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
36 Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma Completed NCT02155920 Phase 2 Everolimus
37 Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
38 A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
39 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
40 Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
41 Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
42 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
43 Phase II Study of Phenylacetate in Pediatric Patients With Central Nervous System Tumors Completed NCT00003241 Phase 2 phenylacetate
44 A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2 Bevacizumab;Lapatinib
45 A Phase II Trial of Intravenous Cereport (RMP-7) and Carboplatin in Childhood Brain Tumors Completed NCT00019422 Phase 2 carboplatin;lobradimil
46 Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy Completed NCT00463203 Phase 2 Bevacizumab;Irinotecan
47 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
48 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
49 A Phase II Trial of Poly ICLC in Patients With Recurrent Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
50 A Phase II Study of Navelbine (Vinorelbine) In Children With Recurrent Or Refractory Malignancies Completed NCT00003234 Phase 2 vinorelbine tartrate

Search NIH Clinical Center for Benign Ependymoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Carmustine

Cochrane evidence based reviews: ependymoma

Genetic Tests for Benign Ependymoma

Anatomical Context for Benign Ependymoma

MalaCards organs/tissues related to Benign Ependymoma:

41
Brain, Spinal Cord, T Cells, Bone, Pineal, Pituitary, Testes

Publications for Benign Ependymoma

Articles related to Benign Ependymoma:

(show top 50) (show all 3556)
# Title Authors PMID Year
1
Cysts associated with intramedullary ependymomas of the spinal cord: clinical, MRI and oncological features. 38
31338784 2019
2
Microsurgical Resection of Low-Grade Spinal Cord Astrocytoma: 2-Dimensional Operative Video. 38
30566660 2019
3
Retrospective Study on Accuracy of Intraoperative Frozen Section Biopsy in Spinal Tumors. 38
31108252 2019
4
Sudden Unexpected Death in a Child From an Anaplastic Ependymoma. 38
30958386 2019
5
Spinal Myxopapillary Ependymoma: The Sapienza University Experience and Comprehensive Literature Review Concerning the Clinical Course of 1602 Patients. 38
31152881 2019
6
Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior. 38
31373367 2019
7
Intracranial Ependymomas: Molecular insights and translation to treatment. 38
31433520 2019
8
[Treatment of benign tumors in thoracic spinal canal by modified replanting posterior ligament complex applying piezoelectric osteotomy]. 38
31407559 2019
9
Childhood cerebellar tumours mirror conserved fetal transcriptional programs. 38
31043743 2019
10
Neurofibromatosis type 2 and related disorders. 38
31425178 2019
11
Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity. 38
30993672 2019
12
Histogram Analysis Parameters ADC for Distinguishing Ventricular Neoplasms of Ependymoma, Choroid Plexus Papilloma, and Central Neurocytoma. 38
31390342 2019
13
[Superficial siderosis of the central nervous system caused by myxopapillary ependymoma of conus medullaris and cauda equine: a case report and literature review]. 38
31420638 2019
14
Integrating ependymoma molecular subgroups into clinical trials. 38
31402383 2019
15
Haemosiderin cap sign in cervical intramedullary schwannoma mimicking ependymoma: how to differentiate? 38
31197414 2019
16
Subgroup-specific outcomes of children with malignant childhood brain tumors treated with an irradiation-sparing protocol. 38
31375903 2019
17
Myxopapillary ependymoma of cauda equina presented with communicating hydrocephalus and papilloedema: A case report. 38
31424046 2019
18
Neuroendoscopic Aspiration of Blood Clots in the Cerebral Aqueduct and Third Ventricle During Posterior Fossa Surgery in the Prone Position. 38
30496503 2019
19
MYCN amplification drives an aggressive form of spinal ependymoma. 38
31414211 2019
20
Detecting the long non‑coding RNA signature related to spinal cord ependymal tumor subtype using a genome‑wide methylome analysis approach. 38
31257484 2019
21
Downregulated long non-coding RNA LINC00899 inhibits invasion and migration of spinal ependymoma cells via RBL2-dependent FoxO pathway. 38
31432742 2019
22
Disparities among racial/ethnic groups of patients diagnosed with ependymoma: analyses from the Surveillance, Epidemiology and End Results (SEER) registry. 38
31209774 2019
23
Report of a case of giant cell ependymoma with unusual clinical and pathological presentation. 38
31243802 2019
24
Outcome of postoperative radiation therapy for pediatric intracranial ependymoma: a single-institution review. 38
31203397 2019
25
Microneurosurgical Removal of a Cervical Intramedullary Tumor Via Hemilaminoplasty: 3-Dimensional Operative Video. 38
30541051 2019
26
5-ALA fluorescence on tumors different from malignant gliomas. Review of the literature and our experience. 38
31355622 2019
27
Augmented reality in intradural spinal tumor surgery. 38
31300886 2019
28
Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. 38
30523344 2019
29
A comparison study assessing neuropsychological outcome of patients with post-operative pediatric cerebellar mutism syndrome and matched controls after proton radiation therapy. 38
31325031 2019
30
Pediatric Supratentorial Ependymoma: Surgical, Clinical, and Molecular Analysis. 38
29917116 2019
31
Anaplastic ependymoma arising from the lower segment of the uterine corpus: Case report and literature review. 38
31060102 2019
32
Canine Ependymoma: Diagnostic Criteria and Common Pitfalls. 38
31266414 2019
33
A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma. 38
31311995 2019
34
Radiation doses to brain substructures associated with cognition in radiotherapy of pediatric brain tumors. 38
31271084 2019
35
Spinal melanotic ependymoma: A case report and review of literature. 38
30871914 2019
36
Current and Emerging Methods of Management of Ependymoma. 38
31359299 2019
37
Notch pathway in ependymoma RELA-fused subgroup: upregulation and association with cancer stem cells markers expression. 38
31308481 2019
38
Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma. 38
31276586 2019
39
New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X. 38
31292491 2019
40
Anaplastic Ependymoma and Posterior Fossa Grouping in a Patient With H3K27ME3 Loss of Expression but Chromosomal Imbalance. 38
31360801 2019
41
TERTp Mutation Detection in Plasma by Droplet-Digital Polymerase Chain Reaction in Spinal Myxopapillary Ependymoma with Lung Metastases. 38
31330336 2019
42
The European Society of Paediatric Oncology Ependymoma-II program Core-Plus model: Development and initial implementation of a cognitive test protocol for an international brain tumour trial. 38
31182404 2019
43
A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells. 38
30929275 2019
44
IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis. 38
31240473 2019
45
Giant intradural extramedullary spinal ependymoma, a rare arachnoiditis-mimicking condition: case report and literature review. 38
31213094 2019
46
Clinical analysis of syringomyelia resulting from spinal hemangioblastoma in a single series of 38 consecutive patients. 38
30999208 2019
47
Survival Differences Between Males and Females Diagnosed With Childhood Cancer. 38
31259303 2019
48
Benign ependymoma with extensive intracranial and spinal cerebrospinal fluid dissemination: case report and literature review. 38
28633540 2019
49
Clinical Importance of Free Thyroxine Concentration Decline after Radiotherapy for Pediatric and Adolescent Brain Tumors. 38
31173083 2019
50
Factors associated with postoperative outcomes in patients with intramedullary Grade II ependymomas: A Systematic review and meta-analysis. 38
31232977 2019

Variations for Benign Ependymoma

Expression for Benign Ependymoma

Search GEO for disease gene expression data for Benign Ependymoma.

Pathways for Benign Ependymoma

Pathways related to Benign Ependymoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.66 TSC2 TSC1 NF2 MTOR
2
Show member pathways
12.06 TSC2 TSC1 MTOR
3 12.03 TSC2 TSC1 MTOR
4
Show member pathways
11.95 TSC2 TSC1 MTOR
5 11.9 TSC2 TSC1 MTOR
6 11.89 TSC2 TSC1 MTOR
7 11.89 SYP RBFOX3 NF2 GFAP ENO2
8 11.87 TSC2 TSC1 MTOR
9
Show member pathways
11.85 TSC2 TSC1 MTOR
10
Show member pathways
11.83 TSC2 TSC1 MTOR
11 11.75 TSC2 TSC1 MTOR
12 11.51 TSC2 TSC1 MTOR
13 11.32 TSC2 TSC1 MTOR
14 11.22 TSC2 TSC1 MTOR
15 11.06 TSC2 TSC1 MTOR
16 11.05 TSC2 MTOR
17 10.98 TSC2 MTOR
18 10.97 TSC2 TSC1 NF2 MTOR
19 10.85 TSC2 TSC1 MTOR
20 10.71 TSC1 MTOR

GO Terms for Benign Ependymoma

Cellular components related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.65 TSC2 TSC1 SGCA RBFOX3 NF2 MTOR
2 TSC1-TSC2 complex GO:0033596 8.62 TSC2 TSC1

Biological processes related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cell cycle GO:0051726 9.54 TSC2 TSC1 NF2
2 negative regulation of TOR signaling GO:0032007 9.48 TSC2 TSC1
3 negative regulation of insulin receptor signaling pathway GO:0046627 9.46 TSC2 TSC1
4 positive regulation of macroautophagy GO:0016239 9.43 TSC2 TSC1
5 regulation of protein kinase activity GO:0045859 9.4 TSC1 MTOR
6 positive regulation of glial cell proliferation GO:0060252 9.32 MTOR GFAP
7 negative regulation of macroautophagy GO:0016242 9.26 TSC1 MTOR
8 anoikis GO:0043276 9.16 TSC2 MTOR
9 negative regulation of cell size GO:0045792 8.96 TSC1 MTOR
10 positive regulation of stress fiber assembly GO:0051496 8.8 TSC1 NF2 MTOR

Molecular functions related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.02 SYP MTOR KCTD1 IDH1 GFAP

Sources for Benign Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....